Articles tagged with Ulcerative Colitis
A new Cochrane Review found that stool transplantation can increase the number of people recovering from Clostridioides difficile (C. diff) infection by 77%, compared to 40% with standard antibiotic treatment. The study also showed a decrease in side effects with stool transplantation.
Patients with inflammatory bowel disease (IBD) are at a higher risk of developing lymphoma, particularly those with Crohn's disease. The risk is driven by both the disease activity and treatment, including immunomodulating drugs.
A UC Riverside-led study found that reduced PTPN2 activity in intestinal epithelial cells leads to decreased Paneth cell antimicrobial peptide production, disrupting the gut microbiota and increasing E. coli. This loss can serve as a marker of IBD disease.
A new study by Oxford researchers has found vedolizumab to be effective in inducing remission in patients with chronic pouchitis after surgery for ulcerative colitis. The treatment improved remission rates and quality of life, making it a game-changer for these patients.
Researchers at University of Birmingham develop AI diagnostic tool to predict ulcerative colitis flare-ups with 89% accuracy. The system identifies markers of inflammation and healing, providing analytical support for clinicians in managing the disease.
Researchers at Georgia State University found that psyllium fiber protects against ulcerative colitis by activating the bile acid nuclear receptor FXR, which suppresses inflammation. The study suggests that pharmacologic activation of FXR might be useful in managing inflammatory bowel disease.
A new study found that individuals with a normal gastrointestinal biopsy still have a higher risk of developing inflammatory bowel disease (IBD) in the years following the biopsy. The study of over 450,000 individuals in Sweden showed that symptoms of IBD may start significantly before the disease shows up on biopsy.
The American Gastroenterological Association recommends integrating non-invasive biomarkers for patients with ulcerative colitis in remission or with current symptoms. Biomarkers provide accurate insights into disease activity, offering a cheaper and more convenient option for monitoring.
Studies elucidate key aspects of traditional Chinese compounds and modern cancer therapeutics, highlighting the efficacy of R. serra in treating colitis and identifying active components of Gan Cao in treating pneumonia. A new radiolabeled antibody-based probe for detecting PD-L1 expression in cancers also provides a novel approach to ...
Researchers have isolated two new bacterial species from patients with inflammatory bowel disease (IBD), which break down the protective mucus layer of the gut. The bacteria, Allobaculum mucilyticum and Allobaculum fili, are highly efficient at degrading intestinal mucus, leading to potent immune responses.
Research suggests that frequent antibiotic use may heighten the risk of inflammatory bowel disease among older adults. The study found a cumulative risk, with the highest risk observed 1-2 years after antibiotic exposure, particularly for those targeting gut infections.
Researchers at McMaster University found that long-term consumption of Allura Red AC can harm gut health and promote inflammation. The study suggests a link between the synthetic food dye and inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.
Salk scientists have developed a new therapeutic compound called FexD, which reverses gut inflammation in mouse models of inflammatory bowel disease. By activating the master regulator protein FXR, FexD reduces inflammation and restores balance to the digestive system.
A large international study found that adopting and maintaining a healthy lifestyle may prevent up to 60% of Crohn's disease and ulcerative colitis cases. The study analyzed data from over 300,000 participants and estimated that a low risk score for inflammatory bowel disease could have prevented a significant proportion of cases if an...
Researchers at Karolinska Institutet have shown that B cells can prevent intestinal healing by increasing in numbers after bowel damage. The study found that mice lacking B cells recovered more quickly after bowel damage than regular mice.
A study by the University of Gothenburg found that women with inactive inflammatory bowel disease (IBD) have a higher risk of giving birth prematurely, particularly if they have microscopic inflammation in their intestinal mucosa. This association was not seen for other adverse pregnancy outcomes, such as growth restriction.
Scientists discover that increased levels of enzyme alpha 1-6 fucosyltransferase (FUT8) in the colon may lead to ulcerative colitis by altering mucous layer properties, making it more permeable and sticky. Researchers believe this allows bacteria to reach epithelial cells, triggering inflammation.
A cohort study found that endoscopists performing colonoscopies in FIT-based screening programs should aim for markedly higher ADRs compared to primary colonoscopy screening. The study suggests that high ADRs are associated with lower colorectal cancer incidence and mortality. Researchers recommend using ADR targets, including differen...
A recent study published in the journal Gut found that gay men are more than twice as likely to develop inflammatory bowel disease (IBD) than heterosexual men who engage in high-risk sexual activity. The study's lead author notes that this finding will open a new field of research into gastrointestinal inflammatory conditions.
Researchers at Georgia State University have discovered a novel way to treat ulcerative colitis using lipid nanoparticles that target the colon with nucleic acids. The treatment showed accelerated healing and reduced inflammation in mice with acute colitis, offering a new gene therapy strategy for IBD treatment.
The TMDU research team successfully transplanted a mini organoid into a patient with Ulcerative Colitis, showing potential for a radical cure. The treatment uses the patient's own cells and minimally invasive colonoscopy, reducing transplant rejection risk and laparotomy needs.
A new study of over 8 million pregnancies found that pregnant women with inflammatory bowel disease (IBD) are at a higher risk of gestational diabetes, postpartum hemorrhage, and other complications. IBD can also lead to longer hospital stays and increased medical costs.
A team from Osaka University developed a silicon-based agent that generates hydrogen when reacting with water, reducing inflammation and symptoms of ulcerative colitis in a mouse model. The study suggests the Si-based agent may be an effective treatment method for this disease.
Researchers developed an AI system that classifies IBDN lesions accurately, displaying image-based diagnostic ability with 64.5% sensitivity and 89.5% specificity. The correct diagnosis rate of the AI system was 79.0, surpassing that of endoscopists, who achieved a 77.8% accuracy rate.
Researchers at Georgia State University developed a personalized treatment to prevent ulcerative colitis in mice by modifying gut microbiota. The study found that orally administering metabolites from treated microbiota provided strong protection against chronic inflammation.
Researchers have found a negative correlation between Helicobacter pylori infection and inflammatory bowel disease (IBD) prevalence, suggesting the bacterium may protect against IBD. This is supported by studies showing improved gut microbiota diversity and increased abundance of beneficial bacteria in H. pylori-infected individuals.
A study of 2.3 million patient records found that antibiotic use was associated with a higher risk of developing inflammatory bowel disease in older adults. The risk increased substantially with each course of antibiotics, with patients who received five or more courses being over 2.3 times more likely to be diagnosed with the condition.
A study of 2.3 million patient records found that antibiotic use was associated with a higher risk of developing inflammatory bowel disease in seniors, particularly those who received multiple courses. The risk increased substantially with each course of antibiotics prescribed.
Researchers at Weill Cornell Medicine found that certain Candida albicans yeast strains produce a potent toxin called candidalysin, which damages immune cells and triggers pro-inflammatory responses. The study suggests a possible way to personalize treatments for IBD patients by targeting these high-damaging strains.
Researchers have discovered a potential new diagnostic marker for ulcerative colitis, identifying high levels of antibodies targeted at endothelial protein C receptors in patients with inflammatory bowel disease. The discovery could lead to the development of non-invasive blood tests to diagnose and track the progression of the disease.
A team led by Case Western Reserve University discovered the novel repair properties of Gasdermin B protein, promoting restoration of epithelial layers and effective wound-healing. The findings have significant implications for designing therapeutics to enhance wound repair in various organs.
A study published in Nature Microbiology reveals that a class of microbial enzymes contributes to ulcerative colitis. Researchers identified an overabundance of proteases from the gut resident Bacteroides vulgatus in nearly 40% of patients, which can exacerbate the disease when not treated with protease inhibitors.
Researchers discovered that people with inflammatory bowel disease (IBD) have higher levels of microplastics in their feces compared to healthy individuals. The study suggests a possible link between microplastic exposure and IBD, but the exact relationship remains unclear.
Researchers at UC Riverside have discovered that targeting the TNFR1 receptor may be a more effective approach to treating inflammatory bowel disease. By selectively blocking TNFR1, they found significant benefits in mice with Crohn's-like ileitis, suggesting this approach could offer a new opportunity for healing.
Researchers developed an AI system to detect inflammation in ulcerative colitis patients using live colonoscopy videos. The system accurately predicted remission cases with high accuracy, reducing the need for invasive biopsies.
Researchers have identified a link between certain gut microbiome molecules and the immune system protein P-gp, which plays a critical role in gut inflammation. The study suggests that supporting a healthy balance of microbes in the gut may help regulate P-gp expression and prevent chronic inflammation.
Researchers at Osaka University found that E-NTPD8 regulates luminal ATP levels, which affects immune cells and promotes inflammation in colitis. Depletion of neutrophils improved symptoms, highlighting the enzyme's role in preventing severe colitis.
Researchers found statins significantly decrease the rate of surgical treatment, anti-inflammatory medication use, and hospitalization for patients with ulcerative colitis. Patients taking statins had a 50% lower risk of colectomy and were less likely to be hospitalized.
Researchers identified predictive molecular biomarkers for non-response to anti-TNF and anti-integrin therapies in UC. Biomarkers in innate and adaptive immune systems, as well as proteolytic degradation, were found to be predictive of therapy non-response.
A new study from the University of Gothenburg suggests that defective goblet cells may contribute to ulcerative colitis by damaging the mucus protection layer. The research team identified specific types of goblet cells and found that their premature rejection leads to inflammation and increased cancer risk.
A study found that surgery to repair an inflamed gut may trigger a second immune system attack, which could lead to pouchitis. Researchers analyzed tissue samples and gene activity in patients who developed pouchitis after J-pouch surgery.
Researchers developed a novel, patient-derived model of ulcerative colitis to identify promising targets for new treatments. The model showed that inhibiting CXCL8 expression slowed disease progression.
A large study found that antibiotic use, especially broad-spectrum antibiotics, is associated with an increased risk of new-onset inflammatory bowel disease (IBD) and its subtypes. The study suggests that perturbing the gut microbiome may impact the risk of gastrointestinal disease.
A new special issue of Clinical Gastroenterology and Hepatology highlights major advances in IBD treatment. The issue provides comprehensive updates on algorithmic treatments to reduce morbidity and emphasizes the importance of treating beyond symptom relief.
Researchers at Flinders University have discovered a complex array of sensory nerve endings in the lower colon that can detect sensory stimuli and communicate with the spinal cord. This breakthrough could lead to new medications to treat disorders related to gut-to-brain communication.
Researchers developed an AI system that evaluates endoscopic mucosal findings in UC patients with accuracy equivalent to expert endoscopists. This may reduce the need for invasive procedures like biopsies, saving time and money for medical institutions.
A study by Stanford University School of Medicine investigators found that patients with ulcerative colitis have depleted levels of secondary bile acids and Ruminococcaceae bacteria in their intestines. These findings suggest that supplementing or restoring these missing metabolites may effectively treat intestinal inflammation.
Breakthrough research presents five major advances in inflammatory bowel disease (IBD) treatment, including a new drug pipeline, a diet that improves symptoms, and a fecal microbiota transplantation approach. These studies offer hope for patients with Crohn's disease and ulcerative colitis.
The new clinical guideline provides recommendations for immunomodulators, biologics, and small molecules to bring on and maintain remission in adult outpatients with moderate to severe UC. It also suggests early use of biologics with or without immunomodulator therapy.
Patients with ulcerative colitis have a significantly elevated risk of developing and dying of colorectal cancer, even with modern therapy. A large study found that these patients have a 66% higher chance of being diagnosed with colorectal cancer compared to the control group.
Researchers at UC Riverside found that the drug tofacitinib repairs permeability defects in the gut's epithelium, reducing inflammation and improving mucosal healing. The study is the first to show the direct effect of tofacitinib on intestinal epithelial cell functions.
Researchers conducted the world's first international study to compare two new drugs for treating ulcerative colitis. The results published in The New England Journal of Medicine show Vedolizumab as 9-12% more effective than Adalimumab in treating moderate to severe forms of the disease.
A new study found that IBD cases are three times higher than previously reported, with ulcerative colitis and Crohn's Disease prevalence increasing by 55% and 83%, respectively. The study also predicts a rise in IBD prevalence by almost a quarter from 2017 to 2025.
Landos Biopharma has completed a $60 million Series B financing round to support global Phase 2 clinical trials of its lead product BT-11 for ulcerative colitis and Crohn's disease. The funding will also advance additional pipeline candidates, addressing an unmet clinical need for new therapies in inflammatory bowel disease.
A new study by researchers at UConn Health and Texas A&M University found that walnut consumption provided protection against experimentally-induced ulcerative colitis in mice. The study showed that walnuts reduced inflammation and enhanced the repair process of the colon, leading to less injury during an episode of ulcerative colitis.
Researchers found that smoking did not reduce flares, medication use, hospitalizations, or colon surgery in patients with UC. Smoking cessation also did not worsen the course of disease.
Researchers found that Edinburgh has the highest rate of inflammatory bowel disease globally, with one in 98 people expected to be affected by 2028. The study highlights the need for more resources to provide patients with research, treatment, and care.
Researchers at Karolinska Institutet have developed a new method to divide patients with ulcerative colitis into two groups based on conserved gene expression across species. The study found that 87% of patients in one group responded poorly to treatment, while 60% in the other group showed improvement.
A study found that infliximab, a biologic therapy, did not result in lower rates of hospitalizations or intestinal surgeries among patients with inflammatory bowel diseases (IBD) in Ontario. Despite improving symptoms for individual patients, the treatment's impact on quality of life and workplace productivity remains uncertain.
Studies highlight the importance of treating IBD as a whole person, including reproductive and mental health aspects. Patient-provider communication is key to improving health outcomes and addressing emotional exhaustion associated with IBD.